Andrew Enrietti
Chief Administrative and Transformation OfficerViatris
PharmaceuticalsView Profile →Senior Vice President, Antibody Technology, Oncology and Research · Regeneron Pharmaceuticals
John Lin is senior vice president of antibody technology, oncology and research at Regeneron Pharmaceuticals. He joined in 2016 after research and early biologics development at Pfizer, Rinat Neuroscience and Genentech.
Last reviewed: Oct 21, 2026
Senior Vice President, Antibody Technology, Oncology and Research Regeneron Pharmaceuticals
Last Reviewed: October 21, 2026
John Lin is senior vice president of antibody technology, oncology and research at Regeneron Pharmaceuticals. He joined in 2016 after research and early biologics development at Pfizer, Rinat Neuroscience and Genentech.
Lin completed a postdoctoral fellowship at Genentech before working at Rinat Neuroscience Corporation. He subsequently spent ten years at Pfizer, focused on research and early development of biologics.
He joined Regeneron in 2016. His current leadership includes the oncology and immuno-oncology therapeutic focus area, conditioning and cell medicine, and preclinical bispecific antibody research across disease areas.
The role brings antibody technology together with oncology research and cell medicine. His background combines medical training at National Taiwan University, doctoral study at Harvard and research experience in several biotechnology and pharmaceutical organizations.
Lin earned an MD from National Taiwan University and a PhD from Harvard University.